ABSTRACT
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Oxidative stress and inflammation play a major role in IBS. Considering the antioxidant properties of ellagic acid (EA), this study was designed to evaluate the effect of EA on oxidative stress index, inflammatory markers, and quality of life in patients with IBS. This research was conducted as a randomized, double-blind, placebo-controlled clinical trial; 44 patients with IBS were recruited. Patients who met the inclusion criteria were randomly allocated to consume a capsule containing 180 mg of EA per day (n = 22) or a placebo (n = 22) for 8 weeks. Serum levels of total antioxidant capacity (TAC), malondialdehyde (MDA), C-reactive protein (CRP), and interleukin-6 (IL-6) were measured at the beginning and the end of the study. Also, quality of life was assessed using a self-report questionnaire for IBS patients (IBS-QOL). At the end of the study, we saw a significant decrease and increase in the MDA and TAC in the intervention group, respectively (p < 0.05). Also, EA consumption reduced CRP and IL-6 levels, and these changes were significant in comparison with placebo group changes (p < 0.05). The overall score of IBS-QOL significantly decreased, and quality of life was increased (p < 0.05), but there were no significant changes in the placebo group. According to these findings, receiving polyphenols, such as EA, may help maintain intestinal health by modulating inflammation and oxidative stress and ultimately improving the quality of life in IBS patients. Trial Registration: Iranian Registry of Clinical Trials Identifier: IRCT20141025019669N11.
ABSTRACT
BACKGROUND & AIMS: Weight loss after proper diet is one of the main topics in nutrition. This study was designed to evaluate the effects of probiotic and alpha-Lipoic acid (ALA) supplements on the anthropometric indicators and maintenance of weight in overweight individuals. METHODS: This study consisted of two phases of weight loss (8 weeks) and weight maintenance (16 weeks). Eighty-eight overweight participants were randomly divided into 4 groups in phase 1: isocaloric diet with probiotic (500 mg), an isocaloric diet with ALA (600 mg) and probiotic, an isocaloric diet with ALA and isocaloric diet with placebo. In phase 2, participants received a normal diet with the mentioned supplements. In the beginning, end of the phase 1, and at the end of phase 2, weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), body fat percentage, and blood pressure (BP) were measured. Also, 10 cc blood samples were taken from subjects to measure C-reactive protein (CRP). Data was analyzed using SPSS software. RESULTS: At the end of the two phases, the differences of changes in the probiotic + ALA group was significant in weight, WC, and CRP factors when compared to the other groups (P < 0.05). Also, at the end of the study, maintain a reduced weight was significantly higher in the probiotic + ALA group than in the other groups (P < 0.05). CONCLUSION: According to findings, probiotics and ALA supplementation with normal diet help to maintain decreased weight after adhering to a weight loss diet. This may be due to the reduction of inflammation. TRIAL REGISTRATION: (IRCT20141025019669N10).
Subject(s)
Probiotics , Thioctic Acid , Diet, Reducing , Dietary Supplements , Humans , Obesity , OverweightABSTRACT
BACKGROUND: Inflammatory bowel disease (IBD) as a chronic and debilitating disease is affected by sleep disturbance which increases the risk of malignancy. Sleep disturbance is more common in irritable bowel syndrome (IBS) and few reported studies have assessed its role in IBD. We evaluated the effect of IBS on sleep quality and quality of life (QOL) of IBD patients in clinical remission. METHODS: In a cross-sectional study, 115 IBD patients in clinical remission aged from 14 to 70 years referred to gastroenterology outpatient departments and private gastroenterology offices from 2007 to 2016. Patients considered in four groups (with/without IBS). The Revised "Rome III criteria" used for diagnosing IBS. Pittsburgh Sleep Quality Index questionnaire and the health-related QOL questionnaire used for evaluating sleep quality and QOL. RESULTS: About 85 (73.9%) cases had ulcerative colitis (UC) and 30 (26.1%) cases had Crohn's disease (CD). Forty (34.8%) cases had IBD + IBS. Poor sleep quality in UC + IBS (OR: 0.018, P = 0.003) and UC (OR: 0.016, P = 0.002) was less than CD. Diseases extent in left side colitis (OR: 0.064, P = 0.016) were less than with pancolitis. Sleep quality affected by quality of life (IBDQ) (P = 0.048). Mean quality of life (IBDQ) in patients who had poor sleep was 11% less than those with good sleep. CONCLUSIONS: The syndrome of IBS affects the sleep quality of IBD in clinical remission, especially in CD. Its additive effect with IBD may worsen symptoms that correlated with sleep disturbance, such as pain, psychological and physical condition, and QOL.
ABSTRACT
BACKGROUND: Helicobacter pylori (H.pylori) infection causes multiple upper gastrointestinal diseases but optimal therapeutic regimen which can eradicate infection in all the cases has not yet been defined. This study was designed to evaluate the efficacy of triple levofloxacin-based versus clarithromycin-based therapy. METHODS: In this open-label randomized clinical trial study 120 patients who had esophagogastroduodenoscopy (EGD) with positive rapid urease test (RUT) were enrolled and divided into 2 groups. Case group was treated with levofloxacin (500 mg daily) plus amoxicillin (1 gr twice a day) plus omeprazole (20 mg daily) for 2 weeks. Control group was treated with clarithromycin (500 mg twice a day) plus omeprazole (20 mg daily) for 2 weeks. After the main course of treatment, they received maintenance treatment with omeprazole for 4 weeks. Stool antigen test was performed on them after two weeks of not having any medicine. RESULTS: H.pylori eradication (intention to treat analysis) was successful in 75% of case group and 51.7% of control group showing a significant difference (P=0.008). H.p infection eradication (per-protocol analysis) was successful in 80.4% in case group and 57.4%% in control group showing significant difference (P=0.009). Drugs adverse effects causing discontinuation treatment were seen in 5% of case group and 3.3% of control group which have not shown a significant difference between the two groups (P=0.648). CONCLUSION: Triple therapy with levofloxacin-based regimen has better efficacy than clarithromycin-based regimen and as safe as it is.
